About Vipragen
Vipragen is a company based in Bengaluru (India) founded in 2012 by Chandrashekaran Siddamadappa and Umesh Devurkar. Vipragen has raised $1.48 million across 6 funding rounds from investors including Conscience Multi Family Office, Startup Karnataka and KITVEN. The company has 75 employees as of March 27, 2024. Vipragen operates in a competitive market with competitors including Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
- Headquarter Bengaluru, India
- Employees 75 as on 27 Mar, 2024
- Founders Chandrashekaran Siddamadappa, Umesh Devurkar
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Vipragen Biosciences Private Limited
- Date of Incorporation 11 May, 2012
- Jurisdiction Mysore, Karnataka, India
-
Annual Revenue
$840.53 K (USD)1.77as on Mar 31, 2023
-
Net Profit
-$115.71 K (USD)-796.89as on Mar 31, 2023
-
EBITDA
$41.42 K (USD)-60.36as on Mar 31, 2023
-
Total Equity Funding
$1.48 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Conscience Multi Family Office
& 17 more
-
Employee Count
75
as on Mar 27, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Vipragen
Vipragen has successfully raised a total of $1.48M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Vipragen
Vipragen has secured backing from 18 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Conscience Multi Family Office, Startup Karnataka and KITVEN.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed by government financial institutions focused on early and growth stage startups
|
Locked | Locked | Locked | |
|
Offers wealth management, estate planning, tax reduction, and insurance services to families.
|
Locked | Locked | Locked | |
|
Support for startups in Karnataka is delivered through policies, funding, and networking services.
|
Locked | Locked | Locked |
Investor details for Vipragen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Vipragen
Investment portfolio details for Vipragen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Vipragen
Detailed financials for Vipragen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Vipragen Comparisons
Peer comparison for Vipragen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Vipragen
Vipragen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evotec, Crown Bioscience, Alloy Therapeutics, Domainex and NIH, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug discovery and development services are provided to biopharma sector.
|
|
| Locked | Locked | Locked |
Cancer and CVMD drugs are developed using PDX models.
|
|
| Locked | Locked | Locked |
Drug discovery services are provided for therapeutic development.
|
|
| Locked | Locked | Locked |
Drug discovery CRO company for epigenetic research and inflammatory diseases
|
|
| Locked | Locked | Locked |
Drug discovery services are provided to the biopharma sector.
|
|
| Locked | Locked | Locked |
Drug discovery and development research services are provided.
|
Detailed competitors of Vipragen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Vipragen
Complete news archive for Vipragen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vipragen
Vipragen was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Vipragen is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Vipragen is a funded company, having raised a total of $1.48M across 6 funding rounds to date.
As of Mar 27, 2024, the latest employee count at Vipragen is 75.
Annual revenue of Vipragen is $840.53K as on Mar 31, 2023.
The company was founded in 2012 in Bengaluru, India, within the pharmaceutical sector. Drug discovery and development services are offered, focusing on evaluation of potential compounds for safety and effectiveness. Operations cover the full spectrum from target validation to clinical candidature, supported by molecular modeling. Thorough testing is conducted to advance compounds through the development process.
Vipragen's top competitors include Evotec, Crown Bioscience and NIH.
Vipragen has 18 investors. Key investors include Conscience Multi Family Office, Startup Karnataka, KITVEN, Pratibha Umesh Devurkar, and K S Manjunath Naidu.
The valuation of Vipragen is $5.7M as of May 2019.